Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Monitoring of Immune Checkpoint Inhibitors Adverse Drug Reactions Through the WHO Vigilyze and French Pharmaco-vigilance Database (Base Nationale de Pharmacovigilance BNPV)

Trial Profile

Monitoring of Immune Checkpoint Inhibitors Adverse Drug Reactions Through the WHO Vigilyze and French Pharmaco-vigilance Database (Base Nationale de Pharmacovigilance BNPV)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Jul 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Avelumab (Primary) ; Durvalumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Tremelimumab (Primary)
  • Indications Arthritis; Autoimmune disorders; Bladder cancer; Breast cancer; Cancer; Cardiovascular disorders; Endocrine disorders; Endometrial cancer; Gastrointestinal cancer; Glioblastoma; Hodgkin's disease; Liver cancer; Lung cancer; Malignant melanoma; Myeloma; Ovarian cancer; Pancreatic cancer; Renal cancer; Skin cancer
  • Focus Adverse reactions
  • Acronyms CHIMeRA
  • Most Recent Events

    • 11 Oct 2018 Status changed from recruiting to completed.
    • 13 Jul 2018 Planned End Date changed from 30 Jun 2018 to 30 Jun 2023.
    • 13 Jul 2018 Planned primary completion date changed from 30 Jun 2018 to 30 Jun 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top